661 related articles for article (PubMed ID: 22766086)
1. My treatment approach to rheumatoid arthritis.
Davis JM; Matteson EL; ;
Mayo Clin Proc; 2012 Jul; 87(7):659-73. PubMed ID: 22766086
[TBL] [Abstract][Full Text] [Related]
2. Treatment, management, and monitoring of established rheumatoid arthritis.
Bingham CO; Miner MM
J Fam Pract; 2007 Oct; 56(10 Suppl Rapid):S1-7; quiz S8. PubMed ID: 17949607
[No Abstract] [Full Text] [Related]
3. Biological therapy for rheumatoid arthritis: where are we now?
Horton SC; Emery P
Br J Hosp Med (Lond); 2012 Jan; 73(1):12-8. PubMed ID: 22241404
[TBL] [Abstract][Full Text] [Related]
4. [New ways in the management of rheumatoid arthritis in Hungary].
Gergely P; Poór G
Lege Artis Med; 2007 Oct; 17(10):657-64. PubMed ID: 19227595
[TBL] [Abstract][Full Text] [Related]
5. Risk and severity of herpes zoster in patients with rheumatoid arthritis receiving different immunosuppressive medications: a case-control study in Asia.
Liao TL; Chen YM; Liu HJ; Chen DY
BMJ Open; 2017 Jan; 7(1):e014032. PubMed ID: 28057661
[TBL] [Abstract][Full Text] [Related]
6. [The meaning of biologic therapy in the treatment of rheumatoid arthritis with the focus on clinical remission. Part II. Tocilizumab, Abatacept, Rituximab--drugs characterised by a different mechanism of action than TNF-alpha inhibitors].
Swierkot J; Madej M
Pol Merkur Lekarski; 2011 Apr; 30(178):289-94. PubMed ID: 21595177
[TBL] [Abstract][Full Text] [Related]
7. Approaches to the treatment of early rheumatoid arthritis with disease-modifying antirheumatic drugs.
Sizova L
Br J Clin Pharmacol; 2008 Aug; 66(2):173-8. PubMed ID: 18537958
[TBL] [Abstract][Full Text] [Related]
8. [Biologicals in the treatment of rheumatic diseases].
Scherer HU; Burmester GR
Dtsch Med Wochenschr; 2006 Oct; 131(41):2279-85. PubMed ID: 17036270
[No Abstract] [Full Text] [Related]
9. Treatment of juvenile idiopathic arthritis in the biologic age.
Stoll ML; Cron RQ
Rheum Dis Clin North Am; 2013 Nov; 39(4):751-66. PubMed ID: 24182853
[TBL] [Abstract][Full Text] [Related]
10. Predictive factors of response to biological disease modifying antirheumatic drugs: towards personalized medicine.
Daïen CI; Morel J
Mediators Inflamm; 2014; 2014():386148. PubMed ID: 24523570
[TBL] [Abstract][Full Text] [Related]
11. [Non-TNF biologicals in the therapeutic strategy for rheumatoid arthritis].
Wollenhaupt J; Krüger K
Z Rheumatol; 2010 Sep; 69(7):618-25. PubMed ID: 20703488
[TBL] [Abstract][Full Text] [Related]
12. Perspectives on rheumatoid arthritis for the orthopedic surgeon: overview of non-tumor necrosis factor biologic drugs and perioperative management.
Keith MP
Am J Orthop (Belle Mead NJ); 2011 Dec; 40(12):E272-5. PubMed ID: 22268021
[TBL] [Abstract][Full Text] [Related]
13. The use of biological agents in the treatment of rheumatoid arthritis.
Fan PT; Leong KH
Ann Acad Med Singap; 2007 Feb; 36(2):128-34. PubMed ID: 17364080
[TBL] [Abstract][Full Text] [Related]
14. Alternative tumour necrosis factor inhibitors (TNFi) or abatacept or rituximab following failure of initial TNFi in rheumatoid arthritis: the SWITCH RCT.
Brown S; Everett CC; Naraghi K; Davies C; Dawkins B; Hulme C; McCabe C; Pavitt S; Emery P; Sharples L; Buch MH
Health Technol Assess; 2018 Jun; 22(34):1-280. PubMed ID: 29900829
[TBL] [Abstract][Full Text] [Related]
15. A two-step treatment strategy trial in patients with early arthritis aimed at achieving remission: the IMPROVED study.
Heimans L; Wevers-de Boer KV; Visser K; Goekoop RJ; van Oosterhout M; Harbers JB; Bijkerk C; Speyer I; de Buck MP; de Sonnaville PB; Grillet BA; Huizinga TW; Allaart CF
Ann Rheum Dis; 2014 Jul; 73(7):1356-61. PubMed ID: 23716067
[TBL] [Abstract][Full Text] [Related]
16. Methotrexate in combination with other DMARDs is not superior to methotrexate alone for remission induction with moderate-to-high-dose glucocorticoid bridging in early rheumatoid arthritis after 16 weeks of treatment: the CareRA trial.
Verschueren P; De Cock D; Corluy L; Joos R; Langenaken C; Taelman V; Raeman F; Ravelingien I; Vandevyvere K; Lenaerts J; Geens E; Geusens P; Vanhoof J; Durnez A; Remans J; Vander Cruyssen B; Van Essche E; Sileghem A; De Brabanter G; Joly J; Meyfroidt S; Van der Elst K; Westhovens R
Ann Rheum Dis; 2015 Jan; 74(1):27-34. PubMed ID: 25359382
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Beresniak A; Baerwald C; Zeidler H; Krüger K; Neubauer AS; Dupont D; Merkesdal S
Clin Exp Rheumatol; 2013; 31(3):400-8. PubMed ID: 23464803
[TBL] [Abstract][Full Text] [Related]
18. Abatacept with methotrexate versus other biologic agents in treatment of patients with active rheumatoid arthritis despite methotrexate: a network meta-analysis.
Guyot P; Taylor P; Christensen R; Pericleous L; Poncet C; Lebmeier M; Drost P; Bergman G
Arthritis Res Ther; 2011; 13(6):R204. PubMed ID: 22151924
[TBL] [Abstract][Full Text] [Related]
19. Strategies after the failure of the first anti-tumor necrosis factor alpha agent in rheumatoid arthritis.
Papagoras C; Voulgari PV; Drosos AA
Autoimmun Rev; 2010 Jun; 9(8):574-82. PubMed ID: 20433955
[TBL] [Abstract][Full Text] [Related]
20. Treating to target in established rheumatoid arthritis: Challenges and opportunities in an era of novel targeted therapies and biosimilars.
Woodworth TG; den Broeder AA
Best Pract Res Clin Rheumatol; 2015; 29(4-5):543-9. PubMed ID: 26697765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
